Sponsor: Numab Therapeutics AG
Sponsor Study ID: NM032-2668-101
Study Title: A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors
CTO #: 103981
NCT Number: NCT06299163
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung, Soft Tissue, Ovary, Breast
Study Objectives: To assess the safety and tolerability of NM32-2668. To determine the maximum tolerated dose (MTD) sequence of NM32-2668. o determine the Recommended Phase 2 Dose (RP2D) sequence(s) for NM32-2668.